Dissolution

Dissolution
Mr. Sagar Kishor Savale
[Department of Pharmacy (Pharmaceutics)]
2015-016
avengersagar16@gmail.com 1Monday, December 07, 2015

Content
1. Introduction
2. Important Terminology
3. Dissolution
4. Mechanism of dissolution
5. Why dissolution studies
6. Importance and application
7. Application of in vitro dissolution studies
8. General application of dissolution
9. Theory's of dissolution
10. Intrinsic dissolution rate
Monday, December 07, 2015 2

Content
11. Factor affecting on dissolution
12. Methods of dissolution
13. In vivo dissolution studies
14. Dissolution pattern
15. In vitro study is more accepted as compared to In vivo study
16. IV – IVC
17. Biopharmaceutical classification system (BCS)
18. Biowaiver
19. Dosage from conducted dissolution study
20. Reference

1. Introduction
 Dissolution is mass transfer process.
 Dissolution is mainly depend on aqueous solubility of drug.
 It is process in which solid mass transfer in liquid medium.
 Dissolution based on four process – 1. wetting 2. solubility 3.
Swelling 4. diffusion.
 Particle size, shape, surface area is important factor can affect
the rate of dissolution of drug.
 The aqueous solubility is increases, increases rate of dissolution
drug

2. Important Terminology
 Dissolution- solid mass transfer process in to liquid medium.
 Diffusion- diffusion is mass transfer process of individual
molecules of atoms having continuous random molecular
motion contain in concentration gradient is known has
Diffusion.
 Dialysis- separation of easily diffusible particle from poorly
diffusible particle through semipermeable Membrane.
 Ultrafiltration- separation of colloidal particle from sub
colloidal particle through semipermeable membrane.

 Osmosis- The passage of solvent molecule into solution through
semipermeable membrane.
 Semipermeable membrane – Thin layer that can separate two phases.
 Steady sate- Mass transfer process is remains constant per unit time.
 Non steady state- Mass transfer process is not remains constant per unit
time.
 Osmotic pressure- The pressure is exerted in walles of semipermeable
membrane through concentration gradient.
 Diffusant(penetrant)- the amount of material transport in
semipermeable membrane.
 Con. Gradient- concentration of material transport in region of high
con. To region of low con.

 R.D.S. ( rate determining step)- event occurs in longer period of time.
 Hydrophilic drug – r.d.s. absorption
 Lipophilic drug – r.d.s. dissolution
 Dosage system-
1) conventional
2) sustained & Controlled release system (Not undergoes disintegration )

3. Dissolution
 Definition- Dissolution is a process in which a solid substance
solubilizes in a given solvent i.e. mass transfer from the solid
surface to the liquid phase.
 Rate of dissolution- is the amount of drug substance that goes
in solution per unit time under standardized conditions of
liquid/solid interface, temperature and solvent composition.

4. Mechanism of Dissolution
 Dissolution is a mass transfer process
 Sink condition – The concentration of receptor compartment is
maintain lower level as compared to Donor compartment is
known as sink condition.
 Non sink condition – The concentration of receptor
compartment is not maintain at lower level as compared to
donor compartment.

5. Why dissolution studies?
1. To show that the release of drug from the tablet is close to
100%.
2. To show that the rate of drug release is uniform batch to batch.
3. And to show that release is equivalent to those batches proven
to be bioavailable and clinically effective.

6. Importance And Applications
 Results from in-vitro dissolution rate experiments can be used to explain the observed
differences in in-vivo availability. (in vivo and in vivo dissolution test)
 Dissolution testing provides the means to evaluate critical parameters such as adequate
bioavailability and provides information necessary to formulator in development of
more efficacious and therapeutically optimal dosage forms. most sensitive and reliable
predictors of in-vivo availability.
 Dissolution analysis of pharmaceutical dosage forms has emerged as single most important
test that will ensure quality of product. (qualitative and quantitative analysis)
 It can ensure bioavailability of product between batches that meet dissolution criteria.
 Ensure batch-to-batch quality equivalence both in-vitro and in-vivo, but also to screen
formulations during product development to arrive at optimally effective products.
 Physicochemical properties of model can be understood needed to mimic in-vivo
environment.
 Such models can be used to screen potential drug and their associated formulations for
dissolution and absorption characteristics. Monday, December 07, 2015
15

7. Application of In vitro dissolution studies
1. Product Development
Important tool during development of dosage form. Aids in guiding the selection of
prototype formulations and for determining optimum levels of ingredients to achieve drug
release profiles, particularly for extended release formulations. Also guides in selection of a
“market-image” product to be used in pivotal in-vivo bioavailability or bioequivalence
studies.
2. Quality Assurance D.T. performed on future production lots and is used to assess the lot-
to-lot performance characteristics of drug product and provide continued assurance of
product integrity/similarity.
3. Product Stability In-vitro dissolution also used to assess drug product quality with respect
to stability and shelf-life. As product age, physicochemical changes to the dosage form may
alter dissolution characteristics of drug product over time. For some products, polymorph
transformations to more stable, and hence less soluble crystalline forms may result in reduced
dissolution rates.

4. Comparability Assessment Also useful for assessing the impact of pre- or post- approval
changes to drug product such as changes to formulation or manufacturing process. Thus, in-
vitro comparability assessment is critical to ensure continued performance equivalency and
product similarity.
5. Waivers Of In-vivo Bioequivalence Requirements In-vitro dissolution testing or drug
release testing may be used for seeking waiver of required product to conduct in-vivo
bioavailability or bioequivalence studies.
8. General Applications of Dissolution
1) Product development
2) Quality assurance
3) Product stability
4) Comparability assessment

9. Theories of Drug Dissolution
I. Diffusion layer model/Film Theory
II. Danckwert’s model/Penetration or surface renewal Theory
III. Interfacial barrier model/Double barrier or Limited solvation
theory.

9.1 Diffusion layer model/Film Theory
 It involves two steps
a. Solution of the solid to form stagnant film or diffusive layer
which is saturated with the drug
b. Diffusion of the soluble solute from the stagnant layer to the
bulk of the solution; this is r.d.s in drug dissolution.

 The rate of dissolution is given by Noyes and Whitney
Where,
dc/dt= dissolution rate of the drug
K= dissolution rate constant
Cs= concentration of drug in stagnant layer
Cb= concentration of drug in the bulk of the solution at time t

Modified Noyes-Whitney’s Equation

 This is first order dissolution rate process, for which the driving
force is concentration gradient.
 This is true for in-vitro dissolution which is characterized by
non-sink conditions.
 The in-vivo dissolution is rapid as sink conditions are
maintained by absorption of drug in systemic circulation i.e.
Cb=0 and rate of dissolution is maximum.

 Under sink conditions, if the volume and surface area of the
solid are kept constant, then
dC = K
dt
 This represents that the dissolution rate is constant under sink
conditions and follows zero order kinetics.

Dissolution rate under non-sink and sink conditions

 Hixon-Crowell’s cubic root law of dissolution takes into
account the particle size decrease and change in surface area,
W0
1/3 – W1/3 = Kt
Where,
W0=original mass of the drug
W=mass of drug remaining to dissolve at time t
Kt=dissolution rate constant.

9.2 Danckwert’s model/Penetration or surface renewal
Theory
 Dankwert takes into account the eddies or packets that are
present in the agitated fluid which reach the solid-liquid
interface, absorb the solute by diffusion and carry it into the
bulk of solution.
 These packets get continuously replaced by new ones and
expose to new solid surface each time, thus the theory is
called as surface renewal theory.

 The Danckwert’s model is expressed by equation

9.3 Interfacial barrier model/Double barrier or
Limited solvation theory
The Diffusion layer model and the Dankwert’s model were based on two assumptions:
1) The rate determining step that controls dissolution is the mass transport.
2) Solid solution equilibrium is achieved at the solid/liquid interface.
According to interfacial barrier model, an intermediate conc. can exist at the interface as
a result of solvation mechanism and is a function of solubility rather than diffusion.
When considering the dissolution of the crystal will have a different interfacial barrier
given by following equation,

G = ki (Cs – Cb)
Where ,
G = dissolution per unit area
Ki = effective interfacial transport constant
 In this theory, the diffusivity D may not be independent of
saturation conc. Cs .
 The interfacial barrier model can be extended to both Diffusion
layer model and the Dankwert’s model.

10. Intrinsic Dissolution rate
 Rate which is independent of rate of agitation, area of solute available,
etc.
 Intrinsic Dissolution Rate (IDR): rate of mass transfer per area of
dissolving surface.
 It is independent of boundary layer thickness and volume of slolvent .

 Thus,
IDR = k1Cs
 IDR measures the intrinsic properties of the drug only as a
function of the dissolution medium, e.g. its pH, ionic strength,
counter ions, etc.)

11. Factor affecting dissolution rate
1. Physicochemical Properties of Drug
2. Drug Product Formulation Factors
3. Processing Factors
4. Factors Relating Dissolution Apparatus
5. Factors Relating Dissolution Test Parameters

1. Physicochemical Properties of Drug
1) Drug Solubility
 Solubility of drug plays a prime role in controlling its dissolution from dosage form.
Aqueous solubility of drug is a major factor that determines its dissolution rate.
Minimum aqueous solubility of 1% is required to avoid potential solubility limited
absorption problems.
 Studies of 45 compound of different chemical classes and a wide range of solubility
revealed that initial dissolution rate of these substances is directly proportional to
their respective solubility.
 Fig shows a log-log plot of solubility of several drug Vs their corresponding intrinsic
rates of dissolution at infinite rotation speed. Evident from graph that compounds
with high solubility exhibit significantly higher dissolution rates.

2) Salt Formation
 It is one of the common approaches used to increase drug solubility and
dissolution rate. It has always been assumed that sodium salts dissolve
faster than their corresponding insoluble acids. Eg. sodium and
potassium salts of Peniciilin G, sulfa drugs, phenytoin, barbiturates etc.
 While in case of Phenobarbital dissolution of sodium salt was slower
than that of weak acid. Same is the case for weak base drug, strong acid
salts, such as hydrochlorides and sulphates of weak bases such as
epinephrine, tetracycline are
 commonly used due to high solubility. However, free bases of
chlortetracycline, methacycline were more soluble than corresponding
hydrochloride salt at gastric pH values, due to common ion suppression.

3) Particle Size
 There is a direct relationship between surface area of drug and its dissolution rate.
Since, surface area increases with decrease in particle size, higher dissolution rates may
be achieved through reduction of particle size.
 Micronization of sparingly soluble drug to reduce particle size is by no means a
guarantee of better dissolution and bioavailability.
 Micronization of hydrophobic powders can lead to aggregation and floatation when
powder is dispersed into dissolution medium. So, mere increase in S.A. of drug does not
always guarantee an equivalent increase in dissolution rate. Rather, it is increase in the
“effective” S.A., or area exposed to dissolution medium and not the absolute S.A. that is
directly proportional to dissolution rate.
 Hydrophobic drugs like phenacetin, aspirin shows decrease in dissolution rate as they
tend to adsorb air at the surface and inhibit their wettability. Problem eliminated by
evacuating surface from adsorbed air or by use of surfactants. So these drugs in-vivo
exhibit excellent wetting due to presence of natural surfactants such as bile salts.

4) Solid State Characteristics
Solid phase characteristics of drug, such as amorphicity, crystallinity, state of hydration and
polymorphic structures have significant influence on dissolution rate.
Anhydrous forms dissolve faster than hydrated form bcz they are thermodynamically more
active than hydrates. Eg. Ampicillin anhydrate faster dissolution rate than trihydrate.
Amorphous forms of drug tend to dissolve faster than crystalline materials. E.g. Novobiocin
suspension, Griseofulvin.
Where in the dissolution rate of amorphous
erythromycin estolate is markedly lower than
the crystalline form of erythromycin estolate.
Metastable (high activation energy)
polymorphic forms have better dissolution than
stable forms.

5) Co-precipitation
Dissolution rate of sulfathiazole could be significantly increased by co-
precipitating the drug with povidone.

2. Drug Product Formulation Factors
 Dissolution rate of pure drug can be altered significantly when mixed with various adjuncts during
manufacturing process such as diluents, dyes, binders, granulating agents, disintegrants and lubricants.
 Generically identical tablet or capsules exhibited differences in their dissolution rates of their active
ingredients.
1) Diluents
 Diluents in capsule & tablet influence the dissolution rate of drug.
 Studies of starch on dissolution rate of salicylic acid tablet by dry double compression process shows three
times increase in dissolution rate when the starch content increase from the 5 – 20 %.
 Here starch particles form a layer on the outer surface of hydrophobic drug particles resulting in imparting
hydrophilic character to granules & thus increase in effective surface area & rate of dissolution.
• Different types of dissolution apparatus utilized affect ranking of different varieties of starch.
With stirring type of agitation, order was potato starch>cornstarch>arrowroot starch>rice
starch. With oscillating type, a different order observed. Corn>rice>arrowroot>potato.
• The dissolution rate is not only affected by nature of the diluent but also affected by excipient
dilution (drug/excipient ratio).
• E.g. in quinazoline comp. dissolution rate increases as the excipient /drug ratio increases
from 3:1 to 7:1 to 11:1.

2) Disintegrants
 Disintegrating agent added before & after the granulation affects the dissolution rate.
 Studies of various disintegrating agents on Phenobarbital tablet showed that when
copagel (low viscosity grade of Na CMC) added before granulation decreased
dissolution rate but if added after did not had any effect on dissolution rate.
 Microcrystalline cellulose is a very good disintegrating agent but at high
compression force, it may retard drug dissolution.
 Starch is not only an excellent diluent but also superior disintegrant due to its
hydrophilicity and swelling property.
 Disintegration and dissolution rate of disintegrants with moderate swelling capacity
depend to a large extent on mixing time of drug/excipient preblende.
 With lubricant. On other hand, disintegrants with strong swelling capacity such as
sodium starch glycolate were hardly affected by mixing time with lubricant.

3) Binders And Granulating Agents
 The hydrophilic binder increase dissolution rate of poorly wettable drug.
 Large amt. of binder increase hardness & decrease disintegration /dissolution rate of tablet.
 Non aqueous binders such as ethyl cellulose also retard the drug dissolution.
 Phenobarbital tablet granulated with gelatin solution provide a faster dissolution rate in
human gastric juice than those prepared using Na – carboxymethyl cellulose or
polyethylene glycol 6000 as binder.
• Gelatin imparted hydrophilic character to hydrophobic drug surface
whereas PEG 6000 formed a poorly soluble complex while NA-CMC
was converted to its less soluble acid form at the low pH of gastric
fluid.
• In Phenobarbital tablet, faster dissolution rate was observed with 10%
gelatin whereas decrease in dissolution rate with 20% gelatin. This
was due to higher concentration which formed a thick film around
tablet.
• Water soluble granulating agent Plasdone gives faster dissolution rate
compared to gelatin.

4) Lubricants
 Lubricants are hydrophobic in nature (metallic stearates) and prolong tablet disintegration time by forming
water repellant coat around individual granules. This retarding effect is most imp factor in influencing rate of
dissolution of solid dosage forms.
 Both amount and method of addition affect the property. It should be added in small amount (1% or less) and
should be tumbled or mixed gently for only very short time. Prolonged mixing the dissolution time.
 However, if an enhancing effect in dissolution of hydrophobic granules is desired, water soluble lubricant such
as SLS or CARBOWAXES may be used.

5) Surfactants
• They enhance the dissolution rate of poorly soluble drug. This is due to lowering of interfacial tension,
increasing effective surface area, which in turn results in faster dissolution rate.
• E.g Non-ionic surfactant Polysorbate 80 increase dissolution rate of phenacetin granules. The increase was
more pronounced when the surfactant was sprayed on granules than when it was dissolved in granulating
agent.
6) Water-soluble Dyes
• Dissolution rate of single crystal of sulphathiazole was found to decrease significantly in presence of FD&C
Blue No.1. The inhibiting effect was related to preferential adsorption of dye molecules on primary dissolution
sources of crystal surfaces. They inhibit the micellar solubilization effect of bile salts on drug.
• Cationic dyes are more reactive in lower conc. than are anionic dyes.
7) Coating Polymers
• Tablets with MC coating were found to exhibit lower dissoln profiles than those coated with HPMC at 37ºC.
The differences are attributed to thermal gelation of MC at temp near 37º, which creates a barrier to dissoln
process & essentially changes the dissoln medium. This mechanism is substantiated by the fact that at temp
below the gel point & at increased agitation, the effect disappears.

3. Processing Factors
1) Method Of Granulation
Granulation process in general enhances dissolution rate of poorly soluble drug. Wet
granulation is traditionally considered superior. But exception is the dissolution profile of
sodium salicylate tablets prepared by both wet granulation and direct compression where
the dissolution was found more complete and rapid in latter case.
A newer technology called as APOC “Agglomerative Phase of Comminution” was found
to produce mechanically stronger tablets with higher dissolution rates than those made by
wet granulation. A possible mechanism is increased internal surface area of granules
produced by APOC method.

2) Compression Force
 The compression process influence density, porosity, hardness, disintegration time & dissolution of tablet.
 First condition, higher compression force increase the density & hardness of tablet, decrease porosity & hence
penetrability of solvent into the tablet retard the wettability by forming a firmer & more effective sealing layer
by the lubricant and in many case tighter bonding between the particle so decrease dissolution rate of tablet.
• Second condition, higher compression force cause deformation, crushing or fracture of drug particles into smaller ones or
convert spherical granules into disc shaped particles with a large increase in the effective surface area so increase in
dissolution rate.
First cond. Second cond. Combination of both conditions can occur
• In short dissolution decrease at lower pressure (better bonding), then increase at higher pressure (crushing effect) and
decrease again with further increase in pressure bcz of extra rebonding and formation of denser tablets with poorer
dissolution characteristics.

3) Drug Excipient Interaction
 These interactions occur during any unit operation such as mixing, milling, blending,
drying, and/or granulating result change in dissolution.
 The dissolution of prednisolone found to depend on the length of mixing time with
Mg-stearate
 Similar as increase in mixing time of formulation containing 97 to 99% microcrystalline
cellulose or another slightly swelling disintegrant result in enhance dissolution rate.
 Polysorbate-80 used as excipient in capsules causes formation of formaldehyde by
autoxidation which causes film formation by denaturing the inner surface of capsule.
This causes decrease in dissoln rate of capsules.

4) Storage Conditions
• Dissolution rate of Hydrochlorthiazide tablets granulated with acacia exhibited decrease in dissolution rate
during 1 yr of aging at R.T. A similar decrease was observed in tablets stored for 14 days at 50-80ºC or for 4
weeks at 37ºC.
• For tablets granulated with PVP there was no change at elevated temperature but slight decrease at R.T.
• Tablets with starch gave no change in dissoln. rate either at R.T. or at elevated temperature.

4. Factors Relating Dissolution Apparatus
1) Agitation
 Relationship between intensity of agitation and rate of dissolution varies considerably
acc. to type of agitation used, the degree of laminar and turbulent flow in system, the
shape and design of stirrer and physicochemical properties of solid.
 Speed of agitation generates a flow that continuously changes the liq/solid interface
between solvent and drug. In order to prevent turbulence and sustain a reproducible
laminar flow, which is essential for obtaining reliable results, agitation should be
maintained at a relatively low rate.
 Thus, in general relatively low agitation should be applied.
1. Basket Method- 100 Rpm
2. Paddle Method- 50-75 rpm

2) Stirring Element Alignment
 The USP / NF XV states that the axis of the stirring element must not deviate more than 0.2 mm from the
axis of the dissolution vessel which defines centering of stirring shaft to within ±2 mm.
 Studies indicant that significant increase in dissolution rate up to 13% occurs if shaft is offset 2-6 mm from
the center axis of the flask.
 Tilt in excess of 1.5 0 may increase dissolution rate from 2 to 25%.
3) Sampling Probe Position & Filter
 Sampling probe can affect the hydrodynamic of the system & so that change in dissolution rate.
 For position of sampling, USP / NF states that sample should be removed at approximately half the distance
from the basket or paddle to the dissolution medium and not closer than 1 cm to the side of the flask.
 Filter material must be saturated with the drug by repeated passage to avoid losses that might go undetected
during the test sampling.
 Accumulation of the particulate matter on the surface may cause significant error in the dissolution testing.

5. Factors Relating Dissolution Test Medium
1) Temperature
 Drug solubility is temperature dependent, therefore careful temperature control during
dissolution process is extremely important.
 Generally, a temp of 37º ± 0.5 is maintained during dissolution determination of oral
dosage forms and suppositories. However, for topical preparations temp as low as 32º and
25º have been used
2) Dissolution Medium
It is very imp factor affecting dissolution and is itself affected by number of factors such as:
A. Effect of pH
 Weak acids, dissoln. rate increases with increase in pH whereas for weak bases, increase
with decrease in pH.

B. Volume of dissolution medium and sink conditions
 Volume generally 500, 900 or 1,000 ml.
 Simulated gastric fluid(SGF) - pH 1.2.
 Simulated intestinal fluid (SIF)- pH 6.8 (not exceed pH 8.0).
 The need for enzymes should be evaluated case-by-case like…. (Pepsin with SGF and pancreatin with SIF
 If drug is poorly soluble, a relatively large amount of fluid should be used if complete dissolution is to be expected.
 In order to minimize the effect of conc. gradient and maintain sink conditions, the conc. of drug should not exceed 10-
15% of its max. Solubility in dissoln. medium selected. For most of the drugs about 1 L is more than sufficient to
maintain sink conditions.
 However, some insoluble drug present a problem as to handling of huge volume of dissoln. medium that would be
required to maintain the sink conditions. For these, different approaches have been tried like….
 Continous flow method where fresh solvent is pumped continuously into dissoln flask at a fixed flow rate while
maintaining a constant volume. (approach 1)
 Use of non-ionic surfactant in conc. above CMC. (approach 2)
 Use of alcoholic solution (10-30%). (approach 3)

C. Deaeration of dissolution medium
• Dissolved air in distilled water could significantly lower its pH and consequently affect the dissolution
rate of drugs that are sensitive to pH changes, weak acids.
• Another effect is to be released from the medium in form of tiny air bubbles. These bubbles collect at the
surface of the dosage forms, thereby acting as a hydrophobic barrier between solvent and solid surface.
This inhibits wetting and reduction of S.A. and lower dissoln. rate.

Dissolution Medium Example
Water Ampicillin caps., butabarbital sodium
tabs.
Buffers Azithromycin caps., paracetamol tabs.
HCL solution Cemetidine tabs.
Simulated gastric fluid Astemizole tabs., piroxicam caps.
Simulated intestinal fluid Valproic caps., Glipizide tabs.
Surfactant solution Clofibrate caps, danazol caps

12. Methods of Dissolution
12.1 Official Methods
12.2 Non-official methods
12.1 Official Method
1. Beaker method
2. closed method
3. Dialysis method

1. Beaker method
 In this type of method can contain in all IP and USP dissolution
apparatus.
 Mechanism - Non sink condition.
12.1.1 IP apparatus – First is Paddle apparatus (IP)
Second is Basket apparatus (IP)
[(IP – Indian Pharmacopeia) , ( USP – United state Pharmacopeia)]

USP apparatus
Apparatus Classification in USP
1. Apparatus 1 (rotating basket)
2. Apparatus 2 (paddle assembly)
3. Apparatus 3 (reciprocating cylinder)
4. Apparatus 4 (flow-through cell)
5. Apparatus 5 (paddle over disk)
6. Apparatus 6 (cylinder)
7. Apparatus 7 (reciprocating holder)

Apparatus Name Drug Product
Apparatus 1 Rotating basket Tablets
Apparatus 2 Paddle Tablets, capsules, modified drug products, suspensions
Apparatus 3 Reciprocating cylinder Extended-release drug products
Apparatus 4 Flow cell Drug products containing low-water-soluble drugs
Apparatus 5 Paddle over disk Transdermal drug products
Apparatus 6 Cylinder Transdermal drug products
Apparatus 7 Reciprocating disk Transdermal drug products
Rotating bottle (Non-USP-NF) Extended-release drug products (beads)
Diffusion cell (Franz) (Non-USP-NF) Ointments, creams, transdermal drug products

Type of dosage form Recommended Apparatus
Solid oral dosage forms Basket, paddle, reciprocating, cylinder, or flow-through cell
(conventional) Basket and paddle
Oral suspensions Paddle , Spin filter
Oral disintegrating tablets Paddle
Chewable tablets Basket, paddle, or reciprocating, cylinder with glass beads
Transdermal - patches Paddle over disk
Topical - semisolids Franz cell diffusion system
Suppositories Paddle, modified basket, or dual, chamber flow-through cell
Chewing gum Special apparatus [European Pharmacopoeia (PhEur)]
Powders and granules Flow-through cell (powder/granule sample cell)
Micro particulate formulations Modified flow-through cell
Implants Modified flow-through cell

USP App DESCRIPTION ROT. Speed dosage Form
I BASKET 50-120 rpm IR, DR, ER
II PADDLE 25-50 rpm IR, DR, ER
III RECIPROCATING CYLINDER 6-35 dpm IR, ER
IV FLOW-THRU CELL N/A ER, POORLY SOLUBLE API
V PADDLE OVER DISK 25-50 rpm TRANSDERMAL
VI CYLINDER N/A TRANSDERMAL
VII RECIPROCATING HOLDER 30 rpm ER

Condition (for all general)
1. Temp. - 37±0.5˚C
2. PH - ±0.05 unit in specified monograph
3. Capacity – 1000 ml
4. Distance between inside bottom of vessel and paddle/basket is maintained at 25±2
mm.
5. For enteric coated dosage form it is first dissolved in 0.1 N HCl & then in buffer of
pH 6.8 to measure drug release. (Limit – NMT 10% of drug should dissolve in the acid
after 2hr.and about 75% of it should dissolve in the buffer after 45 min.

1. USP Apparatus 1
 It is a Basket type of apparatus.
 It is used for highly water soluble drugs
 E.g. lithium acetate tablet (USP)
Phenytoin Sodium (USP)
Parts of Basket type apparatus
1. Cylindrical vessel
2. Water bath
3. Variable speed Motor
4. Basket
5. Sample Withdrawal point (Sample Removing Point)

1. Cylindrical Vessel – It is made by glass and other transporting material
having bottom flask and cylindrical in shape having capacity 900 ml or
1000 ml (1 lit.)
2. Water bath – It is important to maintain the temperature at 37±0.5˚C
3. Variable speed motor - The rotating shaft attached to the variable
speed motor having RPM 25 to 100 rpm .
4. Basket – It is made by stain less still 316 and mesh size is 10, 20, 22,
40, but mesh size 20 is more accepted. It is important to determine the
rate of dissolution of drug.
5. Sample Withdrawal point (Sample Removing Point) – The point is
important to remove sample from dissolution vessel from dissolution
media.

 Useful for: Capsules, Beads, Delayed release / Enteric Coated dosage forms , Floating dosage forms
 Standard volume: 900/1000 ml
 1, 2, 4 liter vessels
 Advantages: 1) more than 200 monographs. 2) Full pH change during the test 3) Can be easily automated which is
important for routine investigation.
 Disadvantages:1) Disintegration-dissolution interaction 2) Hydrodynamic Dead jone under the basket. 3) Degassing is
particularly important 4) Limited volume-----sink condition for poorly soluble drugs.
40 mesh basket 20 mesh basket 10 mesh basket suppository basket

2. USP Apparatus 2
 It is paddle type of apparatus
 It is used for less water soluble drugs.
 Example – 1. danapzole capsule USP
 Parts
1. Cylindrical vessel
2. Water bath
3. Variable speed Motor
4. paddle
5. Sample Withdrawal point (Sample Removing Point)

PTFE coated paddle Solid PTFE coated paddle

1. Cylindrical Vessel – It is made by glass and other transporting material
having bottom flask and cylindrical in shape having capacity 900 ml or
1000 ml (1 lit.)
2. Water bath – It is important to maintain the temperature at 37±0.5˚C
3. Variable speed motor- The rotating shaft attached to the variable speed
motor having RPM 25 to 100 rpm .
4. Paddle – It is made by stain less still 316 and it is used as paddle bleades
and shaft ; It is important to determine the rate of dissolution of drug.
5. Sample Withdrawal point (Sample Removing Point) – The point is
important to remove sample from dissolution vessel from dissolution
media.

 Useful for: Tablets, Capsules, Beads, Delayed release, enteric coated dosage forms Standard volume:
900/1000 ml
 Advantages
1. Easy to use
2. Robust
3. Can be easily adapted to apparatus 5
4. long experience
5. pH change possible
6. Can be easily automated which is important for routine investigations.
 Disadvantages
1. pH/media change is often difficult
2. Hydrodynamics are complex, they vary with site of the dosage form in the vessel (sticking, floating) and
therefore may significantly affect drug dissolution
3. Coning.

Sinkers for floating dosage forms

 Limitations of USP Apparatus 1 and 2
1. USP2 (and USP1) Apparatus has plenty of HYDRODYNAMICS.
2. Complicated 3-dimensional flow generated by the paddle.
3. Significant impact of convective transport –Conditions used (50 – 100 rpm) highly
exaggerates flow in the GI.
4. If Static-tank model used – sink conditions artificially generated to simulate sink in GI.
5. Use of solvents and surfactants non-native to GI.

3. Apparatus 3
 It is a Reciprocating cylindrical apparatus.
 This method adopts the USP disintegration “basket and rack” assembly
for the dissolution test.
 The disks are not used.
 This method is less suitable for precise dissolution testing due to the
amount of agitation and vibration involved.
 E.g. Chlorpheniramine ER tablets, Carbamazepine chewable tablet

 The assembly consists of a set of cylindrical, flat-bottomed glass vessels; a set of glass reciprocating
cylinders; stainless steel fittings (type 316 or equivalent) and screens that are made of suitable nonsorbing
and nonreactive material(polypropelene) and that are designed to fit the tops and bottoms of the
reciprocating cylinders; and a motor and drive assembly to reciprocate the cylinders vertically inside the
vessels.
 The vessels are partially immersed in a suitable water bath of any convenient size that permits holding the
temperature at 37 ± 0.5 during the test.
 The dosage unit is placed in reciprocating cylinder & the cylinder is allowed to move in upward and
downward direction constantly. Release of drug into solvent within the cylinder measured.
 Useful for: Tablets, Beads, controlled release formulations
 Standard volume: 200-250 ml/station
 Advantages: 1) Easy to change the pH-profiles 2) Hydrodynamics can be directly influenced by varying the
dip rate.
 Disadvantages: 1) small volume (max. 250 ml) 2) Little experience 3) Limited data

4. Apparatus IV
 Open Flow through cell
 The assembly consists of a reservoir and a pump for the Dissolution Medium; a flow-through cell; a water
bath that maintains the Dissolution Medium at 37 ± 0.5
 The cell size is specified in the individual monograph.
 The pump forces the Dissolution Medium upwards through the flow-through cell.
 Place the glass beads into the cell specified in the monograph.
 Place 1 dosage unit on top of the beads or, if specified in the monograph, on a wire carrier.
 Assemble the filter head, and fix the parts together by means of a suitable clamping device.
 Introduce by the pump the Dissolution Medium warmed to 37 ± 0.5 through the bottom of the cell to obtain
the flow rate specified in the individual monograph.
 Collect the elute by fractions at each of the times stated.
 Perform the analysis as directed in the individual monograph.

 Useful for: Low solubility drugs, Micro particulates, Implants, Suppositories, Controlled
release formulations Variations: (A) Open system & (B) Closed system .
 Advantages
1. Easy to change media pH
2. PH-profile possible
3. Sink conditions
 Disadvantages
1. Deaeration necessary
2. High volumes of media
3. Labor intensive

5. Apparatus 5
 Modification of Apparatus 2. (Paddle over disk apparatus)
 Here, stainless steel disk designed for holding transdermal
system at the bottom of the vessel.
 The disk/device should not sorb, react with, or interfere with
the specimen being tested.
 The disk holds the system flat and is positioned such that the
release surface is parallel with the bottom of the paddle blade.

 Use the paddle and vessel assembly from Apparatus 2 with the addition of a stainless steel disk assembly
designed for holding the transdermal system at the bottom of the vessel.
 Other appropriate devices may be used, provided they do not sorb, react with, or interfere with the specimen
being tested
 The disk assembly for holding the transdermal system is designed to minimize any “dead” volume between
the disk assembly and the bottom of the vessel.
 The disk assembly holds the system flat and is positioned such that the release surface is parallel with the
bottom of the paddle blade
 The vessel may be covered during the test to minimize evaporation.
 Useful for: Transdermal patches
 Standard volume: 900 ml
 Disadvantages: Disk assemmbly restricts the patch size.
 Borosilicate Glass
 17 mesh is standard (others available)
 Accommodates patches of up to 90mm

US 724 APPARATUS
Transdermal Patch Retainer (Hanson Style)

6. Apparatus 6
 It is Cylindrical apparatus
 Same as apparatus 1,except to replace the basket and shaft with
a S.S. cylinder stirring element.
 Temperature - 32 ± 0.5°
 The dosage unit is placed on the cylinder.
 Distance between the inside bottom of the vessel and cylinder is
maintained at 25 ± 2 mm.

7. Apparatus 7
 Reciprocating disk / Holder
 he assembly consists of a set of calibrated solution containers, a
motor and drive assembly to reciprocate the system vertically.
 Various type of sample holder are used.

 The assembly consists of a set of volumetrically calibrated solution containers made of glass or other
suitable inert material, a motor and drive assembly to reciprocate the system vertically and a set of
suitable sample holders.
 The solution containers are partially immersed in a suitable water bath of any convenient size that
permits maintaining the temperature, inside the containers at 32 ± 0.5
 For Coated tablet drug delivery system attach each system to be tested to a suitable sample holder
(e.g., by gluing system edge with 2-cyano acrylate glue onto the end of a plastic rod or by placing the
system into a small nylon net bag at the end of a plastic rod or within a metal coil attached to a metal
rod).
 For Transdermal drug delivery system attach the system to a suitable sized sample holder with a
suitable O-ring such that the back of the system is adjacent to and centered on the bottom of the disk-
shaped sample holder or centered around the circumference of the cylindrical-shaped sample holder.
Trim the excess substrate with a sharp blade.
 For Other drug delivery systems attach each system to be tested to a suitable holder as described in the
individual monograph.

Suspend each sample holder from a vertically reciprocating shaker such that each system is continuously immersed in an
accurately measured volume of Dissolution Medium within a calibrated container.
Reciprocate at a frequency of about 30 cycles per minute with amplitude of about 2 cm, or as specified in the individual
monograph, for the specified time in the medium specified for each time point.
Perform the analysis as directed in the individual monograph.

8. Simple view of all
dissolution apparatus

2. Open Flow-through Compartment System
 The dosage form is contained in a small vertical glass column
with built in filter through which a continuous flow of the
dissolution medium is circulated upward at a specific rate from
an outside reservoir using a peristaltic or centrifugal pump.
 Dissolution fluid is collected in a separate reservoir.
 E.g. lipid filled soft Gelatin capsule

Advantages
 No stirring and drug particles are exposed to homogeneous,
laminar flow that can be precisely controlled. All the problems
of wobbling, shaft eccentricity, vibration, stirrer position don’t
exist.
 There is no physical abrasion of solids.
 Perfect sink conditions can be maintained.

Dis advantages
 Tendency of the filter to clog because of the unidirectional
flow.
 Different types of pumps, such as peristaltic and centrifugal,
have been shown to give different dissolution results.
 Temperature control is also much more difficult to achieve in
column type flow through system than in the conventional
stirred vessel type.

3. Dialysis System
 Here, dialysis membrane used as a selective barrier between
fresh solvent compartment and the cell compartment containing
dosage form.
 It can be used in case of very poorly soluble rugs and dosage
form such as ointments, creams and suspensions.

12.2 Non – official dissolution method
1. Rotatory filter method
2. Rotatory flask method
3. Rotatory disk method

1. Rotating Filter Method
 It consists of a magnetically driven rotating filter assembly and
a 12 mesh wire cloth basket.
 The sample is withdrawn through the spinning filter for
analysis.

2. Rotating Flask Dissolution Method
 This consists of a spherical flask made of glass and supported
by a horizontal glass shaft that is fused to its sides.
 The shaft is connected to a constant speed driving motor.
 The flask is placed in a constant temperature water bath and
rotates about its horizontal axis.

3. Rotating And Static Disk Methods
 The compound is compressed into non disintegrating disc
 Mounted – One surface is exposed to medium
 Assumption – Surface area remains constant
 Used to determine the intrinsic dissolution rate

13. In vivo Dissolution Studies
 Techniques of In-Vivo Dissolution Testing:
 Product generate AUC that is plasma concentration-time curve.
 Simply definition bioavilable but not bioequivalent.
 AUC are identical within accepted statistical are stated to bioequivalent.
 Dissolution rate data have become the compendial standard for ensuring
continuing therapeutic of various product available to pharmacist.

Factor Affecting In-Vivo Dissolution
1.Gastrointestinal Motility and Presence of Food
2.Gastrointestinal pH
3.Physicochemical Nature of the Drug
4.Pharmacological Effect of Drug on GI Motility

Measurement of In Vivo Dissolution:
A. Indirect Techniques:
1.Loo-Riegelman analysis
2.Statistical moments
3.Deconvolution
B. Direct Techniques:
1.Histroical Aspects
2.Intubation
3.Jobin et al.
4.Gamma scintigraphy
5.Perturbed angular correlation
6.Summation peak ratio
7.Neutron activation

A. Indirect Techniques
1. Loo- Riegelman
• Used for multi compartment system
• More complicated
• Fraction absorbed at any time t is given by:
 (Xp)T= is amount of drug in peripheral compartment as a function of time
 Vc =is apparent volume of distribution
 K10 =is apparent first order elimination rate constant

2.Statistical Movement
 It’s determine the release – rate constant (Kr) and the
absorption – rate constant (Ka).
 Term MAT (mean absorption time) ,the mean time for drug
molecule to absorbed.
 It composite all kinetic process of absorption, distribution, and
elimination.

3.Deconvolution
 It is the process where output (plasma concentration profile) is converted into input (in vivo
dissolution of dosage form).
 The plasma or urinary excretion data obtained in the definitive bioavailability study of MR dosage
form are treated deconvolution.
 The resulting data represent the in vivo input rate of the dosage form.
 It can also be called in vivo dissolution when the rate controlling step is dissolution rate.
 Any deconvolution procedure will produce the acceptable results.

B. Direct technique
1.Histroical aspects:
 It will be of interest to mention the historical aspects of the study of in vivo dissolution.
 Initially ,these investigted were aimed at finding the in vivo disintegration time.
Example:-Barium sulfate.
2.Intubation:
 Invasive technique.
 Routinely used in digestive physiology for feeding patient.

4. Gamma scintigraphy
 It is a noninvasive but involve exposing the subject to
radiation.
 It measuring the gamma rays emitted from radionuclide.
 These system,two radionuclides with different peak energies
can be monitored Simultaneously and independently.

5.Perturbed angular correlation
 To get quantitative assessment of in vivo
dissolution in contrast to disintegration.
 Perturbed angular correlation in conjunction with external scintigraphy.
6.Summation peak ratio:
 The intensity of the summation peak from two gamma photon emitted
successively from a radionuclide is related to the physical and chemical
environment experienced by the intermediate state of the nucleus.

7.Neutron Activation
These of inert excipients in the tablet is another method to study disintegration in
vivo.
studied radiolabeled intact tablets.
It produced barium-139 and erbium-170 by irradiating the enteric-coated tablet
with a neutron flux.
Barium sulfate was incorporated in small quantity in the dosage form.(10mg in a
300mg tablet).

Methods
A. Pharmacokinetic Methods
These are very widely used and based on the assumption that the pharmacokinetic
profile reflects the therapeutic effectiveness of a drug.
 These are INDIRECT METHODS.
 The two major pharmacokinetic methods are
A. plasma level-time studies.
B. Urinary excretion studies.

 Pharmacokinetic parameter
1.Peak plasma concentration (Cmax)-
The point of maximum concentration of drug in plasma is called as peak and the
concentration of drug at peak is known as peak plasma concentration.
2. Time of peak concentration (Tmax)-
The time for drug to reach peak concentration in plasma is called as time of peak
concentration.
3. Area under the curve (AUC)-
It represent the total integrated area under the plasma level time profile and expresses
the total amount of drug that comes into the systemic circulation after its administration.

B. Pharmacodynamics Method
 These methods are complementary to pharmacokinetic approaches and involve DIRECT
measurement of drug effect on a (patho)physiological process as function of time.
 The two pharmacodynamic methods involve determination of bioavilability from:
1.Acute pharmacological response.
2.Therapeutic response

14. Dissolution pattern
 Product Industry First three stages ( Initial stages)

 Pilot Batches (trial Batches)

 In vivo test
 In vitro test


15. In vitro study is more accepted as compared to In
vivo study
 In vivo study are more time consuming , tedious, complex,
expensive, more expenditure, use animal model , the animal
model leads to toxicity. Some time error is occur waste of
animal model.
 In case of in vitro studies are simple, rapid, reproducible, in
expensive, economical,
 Hence in vitro study is more accepted as compared to in vivo
study.

16. IV-IVC
 In vitro – in vivo correlation
 Introduction
 Definition- The predictive mathematical model that describes
the relationship between an in vitro properties of dosageform
and in vivo response of dosage form.
 Bioavailability
The exact rate of absorption of drug from dosage from is
represented by serum concentration time curve.
 Amount of drug reaches to systemic circulation.

 In vitro in vivo study is important is define has the in vitro
dissolution behavior of drug and in vivo bioavailability of drug.
 It is important to maintain the in vitro in vivo relationship.
 It is important to determine rate of dissolution of drug and amount
of drug in systemic circulation.
 It is important to determine the plasma concentration of drug.
 New drug development studies.
 To determine pharmacokinetic and pharmacodynamics
relationship.
 To determine bioavailability.

Objectives of IVIVC
 To ensure the batch to batch consistancy in physiological
performance of drug product.
 Tool as development of new dosage form desired in vitro
performance.
 To assist in validation or setting dissolution specification.

Some of the used quantitative linear method of IVIVC
 Correlation based on plasma level data
Here parameter used for correlating in vitro dissolution with plasma data are…….
In vitro parameters
1. % drug dissolve
2. Rate of dissolution
3. Dissolution rate constant
In vivo parameters
1. % drug absorbed
2. Rate of absorption
3. Absorption rate constant

Correlation based on urinary excretions data
Here dissolution parameter are correlated to the urinary
excreation data.
parameter s correlated are……
1. The amount of drug excreated unchanged in the urine
2. Cumulative amount of drug excreted as function of time, etc.

Correlation based on the pharmacological response
 Here an acute pharmacological effect such as LD50 ED50 in
animals is corelated to any of the dissolution parameter.

Levels of IVIVC
These IVIVC levels have been defined and catagorised in
descending order of usefulness
1. Level A
2. Level B
3. Level C

Level A
 This is highest category of correlation, it represents point to
point relationship between in vitro dissolution and in vivo rate
of absorption.
 The in vitro dissolution and in vivo absorption rate curves are
superimposable
 The mathematical description for both curves is the same.
 The curves having same shape.

Advantages
 A point to point correlation is developed. The in vitro
dissolution curve serves as surrogate for in vivo performance.
 Any changes in manufacturing procedure or modification in
formula can be justified without need of additional human
study.
 It serves as indicating quality control procedure for predicting
dosage form performance.

Level B
 It utilises the principles of statistical moment analysis.
 The mean in vitro dissolution time is compared with either
mean residence time or mean in vivo dissolution time.
 Weather such correlation is not point to point correlation since
there are no of in vivo curves that will produce similar mean
residence time value.

Limitations
 It utilises all data, but is non unique as different shaped
absorption /dissolution curves could result in same moment
value.
 This correlation alone fails to justify formulation modification,
manufacturing site change, excipients source change, etc.
 It does not justify the extremes of quality control standards.

Level C
 It is a single point correlation
 It correlates one dissolution time point (i.e. t50%) to one
pharmacokinetic parameter such as AUC, tmax, Cmax.
 This level is generally useful only as a guide in formulation
development or quality control.

Limitations
 It does not reflect the complete shape of plasma level curve
which is critical factor defines the performance of controlled or
sustained release products.
 The correlation is non-unique.
 Thus it can only serves as guide in formulation development
and production, quality control procedure.

17. Biopharmaceutical classification system
(BCS)
 The Biopharmaceutical Classification System was first developed by in 1995, by
Amidon et al & his colleagues.
 Definition
“The Biopharmaceutical Classification System is a scientific framework
for classifying a drug substance based on its aqueous solubility & intestinal
permeability & dissolution rate”.
 To saved time & fast screening is required so drug substances are classified on basis
of solubility & permeability. This classification is called Biopharmaceutical
Classification System.

Factor affecting on Biopharmaceutical Classification System
 The Biopharmaceutical Classification System has been
developed to provide a scientific approach to allow for to
prediction in vivo pharmacokinetics of oral immediate release
(IR) drug product by classifying drug compound based on their
1. Solubility
2. Permeability
3. Dissolution

Solubility
 Solubility
It is a process in which solid can dissolved in liquid in presence of
constant temperature and pressure from saturated solution.is
known has solubility.
It is conducted 4˚c to 37˚c Temperature.
Solubility is important parameter solubility is increases rate of
dissolution is increases.
Solubility is directly proportional to dissolution rate

 Solubility is the ability of the drug to be solution after dissolution.
 The higher single unit dose is completely soluble in 250 ml or less
of aqueous solution at pH 1- 6.8 ( 37˚C ).
 The pH solubility profile determined at 37 ± 1˚C.
 In aqueous media within a pH range of 1 to 7.5
 A minimum of three replicate determination of pH solubility
recommended .
 Shake – Flask or Titration method .

Methods for determination of solubility
 Nephelometric method
 Turbidimetric method
 Direct solubility method
 Equilibrium solubility method
 Ultrafiltration Lc-Ms Method

Permeability
 Permeability of the drug to pass the Biological membrane
which is the lipophilic.
 Permeability is based indirectly based on the extent of
absorption of a drug substance in human.
 Drug substance is considered to be highly permeable, when the
extent of absorption in human determined to be 90% or more of
administered drug or compare to in vivo reference dose.

Determination of Permeability
A) Pharmacokinetics studies in human
1. Mass Balance Studies
2. Absolute Bioavailability Studies
B) Intestinal Permeability Method
C) Instability in the GIT

Determination of Dissolution
 Using USP apparatus I at 100 rpm or USP apparatus II at 50
rpm in 900 ml.
 Dissolution Media ( 900 ml ) – 0.1 N HCl or stimulate Gastric
Fluid USP without enzyme. pH 4.5 buffer & pH 6.8 buffer or
stimulated Intestinal Fluid USP without enzyme.

CLASS SOLUBILITY PERMEABILITY
Class – I High High
Class – II Low High
Class – III High Low
Class – IV Low Low

Class I
 Ideal for oral route administration.
 Drug absorbed rapidly.
 Drug dissolved rapidly.
 Rapid therapeutic action.
 e.g. Metoprolol , Propranolol.

Class II
 Ideal for oral route administration.
 Drug absorbed rapidly.
 Drug dissolved rapidly.
 Rapid therapeutic action.
 e.g. Metoprolol , Propranolol.

Class III
 Oral route for administration.
 Drug absorbance is limited.
 Drug dissolve rapidly.
 e. g.- Cimitidine, Metformin.

Class IV
 Poorly absorbed orally administration.
 Both solubility & permeability limitation.
 Low dissolution rate.
 Slow or low therapeutic action.
 e. g.- Taxol, Clorthiazole.

Class Boundaries
HIGHLY SOLUBLE
 The highest dose strength is soluble in < 250 ml water over a pH range of 1 to 7.5.
 The volume estimate - a glassful (8 ounce)
HIGHLY PERMEABLE
 When the extent of absorption in humans is determined to be > 90% of an
administered dose.
RAPIDLY DISSOLVING
 When > 85% of the labeled amount of drug substance dissolves within 30 minutes
using USP apparatus I or II in a volume of < 900 ml buffer solutions.

18. Biowaiver
The in vivo bioequivalence testing
 Definition
It is an exemption from conducting human bioequivalence studies when
the active ingredients meet certain solubility and
permeability criteria in vitro and when the dissolution profile
of the dosage form meets the requirements for an IR dosage form.

Criteria of Biowaiver
 Rapid and similar dissolution.
 High solubility.
 High permeability.
 Wide therapeutic window.
 Excipient used in dosage form are same as those present in approved drug product.

Application Of Biopharmaceutical Classification System
 To predict in vivo performance of drug product using solubility and permeability measurements.
 Aid in earliest stages of drug discovery research.
 To use in bio waiver considerations.
 For research scientist to decide upon which drug delivery technology to follow or develop.
 Also for the regulation of bioequivalence of the drug product during scale up and post approval.

19. Dosage from conducted dissolution study
1. Immediate release tablet (conventional tablet)
1. Dissolution apparatus – Type 1 and Type 2 (USP)
2. Temperature - 37±0.5˚C
3. Time – 30 min
4. Time of interval – 5, 10, 15, 20, 25, 30.
5. Media – PH 1.2 Acidic Buffer, PH 4.5 Acetate buffer, PH 5.8 Phosphate buffer.
(depending upon tablet)
6. Rpm – 75 -100 rpm
7. Volume – 900 ml

 Procedure – The tablet was added into cylindrical vessel containing 1000 ml dissolution
media having rpm 75 and tem.37±0.5˚C . Dissolution of tablet was conducted 30 min , in 5
min. of interval , after 5 min 5 ml sample was removed and appropriate quantity of sample
take absorbance by using U.V. spectroscopy technique and determine rate of dissolution of
tablet.
2. Sustained release tablet
1. Dissolution apparatus – Type 2 (USP)
3. Time – 180 min
4. Media – PH 1.2 Acidic Buffer, PH 6.8 Phosphate buffer.
5. Rpm – 75 – 100.
6. Volume – 900 ml.

 Procedure - The tablet was added into cylindrical vessel containing 1000 ml PH 1.2 Acidic
media having rpm 75 for next two houres and tem. 37±0.5˚C . Dissolution media was
changes tablet was added in to PH 6.8 Phosphate buffer for next one hour for 10 min of
interval. after 10 min 5 mi sample was removed and appropriate quantity of sample take
absorbance by using U.V. spectroscopy technique and determine rate of dissolution of tablet.
3. Capsule
3. Time – 180 min
4. Media – PH 1.2 Acidic Buffer, PH 6.8 Phosphate buffer.
5. Rpm – 75 – 100.

Procedure - The Capsule was added into cylindrical vessel containing 1000 ml PH 1.2 Acidic
media having rpm 75 for next two hours and tem. 37±0.5˚C . Dissolution media was changes
Capsule was added in to PH 6.8 Phosphate buffer for next one hour for 10 min of interval. after
10 min 5 mi sample was removed and appropriate quantity of sample take absorbance by using
U.V. spectroscopy technique and determine rate of dissolution of Capsule.
4. Suppositories
3. Time – 60 min
4. Time of interval – 10, 20, 30, 40, 50, 60.
5. Media – PH 7.4 Phosphate buffer.
6. Rpm – 50 – 75 rpm

 Procedure – The Suppository was added into cylindrical vessel
containing 1000 ml dissolution media (PH 7.4 Phosphate buffer) having
rpm 75 and tem.37±0.5˚C . Dissolution of Suppository was conducted 60
min , in 10 min. of interval , after 10 min 5 ml sample was removed and
appropriate quantity of sample take absorbance by using U.V.
spectroscopy technique and determine rate of dissolution of
Suppositories.

20. Reference
1. Fonner. D. E, Banker. G. S., Granulation & Tablet Characteristics, In Pharmaceutical Dosage Forms: Tablets. Vol. 2.
Edited by H. Lieberman & L. Lachman, Dekker, New York, 1982, p. 202
2. Leon Lachman, Herbert. A. Lieberman, The Theory and Practice of Industrial Pharmacy, 3rd edition, Varghese
Publishing House, Bombay, 1991, pp. 301-303
3. Brahmankar. D. M., Sunil Jaiswal. B, Biopharmaceutics and Pharmacokinetics—A Treatise, 1st edition, Vallabh
Prakashan, New Delhi, 2006, pp. 19-25
4. Alfred Martin, James Swarbrick, Physical Pharmacy, 3rd edition, Varghese Publishing House, Bombay, 1991, pp. 408-
412
5. Florence, Alexander T. and Siepmann, Juergen (2009). Modern Pharmaceutics Application and Advance. Volume 2nd ,
5th edition. Informa Healthcare, Page no. 34 – 35.
6. Benet, Leslie and William, Addics (ND). Application of the Biopharmaceutical Classification System.
7.www.eufeps.org. (Access Time - 12.45 AM Date- 05 -12- 2015).
8. Budhwaar, V. And Nanda, A. (2012). The Biopharmaceutics Classification System : Present Status and Future
Prospective. International Research Journal of Pharmacy. 3(9), Page No. 7 – 10.

9. Dr. Tipnis H.P. and Dr. Bajaj Amrita, Principles and applications of Biopharmaceutics and
Pharmacokinetics, 1st edition 2002, reprint 2005, career publication, Page no. 332-340.
10. Umesh v. banakar ,pharmaceutical dissolution testing, volume 47,marcel dekkar, inc., new york,p.p.209-
237.
11. Dissolution. (n.d.) American Heritage® Dictionary of the English Language, Fifth E).dition. (2011)

Dissolution

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (20)

Ähnlich wie Dissolution

Ähnlich wie Dissolution (20)

Mehr von Sagar Savale

Mehr von Sagar Savale (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Dissolution